Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 12/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 12/20 | 1.00 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.82 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16659481 | 1.00 | FGFR4 (1.00) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL16659399 | 1.00 | FGFR4 (1.00) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL17728856 | 0.93 | FGFR4 (1.00) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL16659434 | 0.93 | FGFR4 (1.00) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL16659594 | 0.93 | FGFR4 (1.00) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL16665261 | 0.91 | FGFR1 (0.83) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL16659606 | 0.90 | FGFR2 (1.00) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL17728840 | 0.90 | FGFR4 (0.82) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL17728841 | 0.90 | FGFR4 (0.82) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL17728842 | 0.90 | FGFR4 (0.82) | FGFR4FGFR1FGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3421457-B1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2021-10-06 | — | — | EP | disclosed |
| US-10912774-B2 | Pyrimidine FGFR4 inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-02-09 | — | — | US | disclosed |
| US-20200206222-A1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-07-02 | — | — | US | disclosed |
| EP-3421457-A1 | PYRIMIDINE FGFR4 INHIBITORS | Eisai R&D Management Co., Ltd. (JP) | 2019-01-02 | — | — | EP | disclosed |
| EP-3057943-B1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2018-04-25 | — | — | EP | disclosed |
| US-20170360785-A1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-12-21 | — | — | US | disclosed |
| US-9730931-B2 | Pyrimidine FGFR4 inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-08-15 | — | — | US | disclosed |
| US-20170007601-A1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-01-12 | — | — | US | disclosed |
| US-9434697-B2 | Pyrimidine FGFR4 inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-09-06 | — | — | US | disclosed |
| US-20160130237-A1 | PYRIMIDINE FGFR4 INHIBITORS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360785-A1 | PYRIMIDINE FGFR4 INHIBITORS | FGFR4, FGFR1, FGFR3 | FGFR4 1/4885FGFR1 2/4885FGFR2 4/4885 |
| US-10912774-B2 | Pyrimidine FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | FGFR4 1/4885FGFR1 2/4885FGFR2 4/4885 |
| US-20160130237-A1 | PYRIMIDINE FGFR4 INHIBITORS | FGFR4, FGFR1, FGFR3 | FGFR4 1/4885FGFR1 2/4885FGFR2 4/4885 |
| US-20170007601-A1 | PYRIMIDINE FGFR4 INHIBITORS | FGFR4, FGFR1, FGFR3 | FGFR4 1/4885FGFR1 2/4885FGFR2 4/4885 |
| US-20200206222-A1 | PYRIMIDINE FGFR4 INHIBITORS | FGFR4, FGFR1, FGFR3 | FGFR4 1/4885FGFR1 2/4885FGFR2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.